{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:21:28Z","timestamp":1777670488090,"version":"3.51.4"},"reference-count":53,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:p>With efficient transduction across most cell types and larger packaging capacity, Adenovirus 5 (Ad5) makes an attractive choice as a viral vector. However, a reported past mortality and known immunogenicity cast doubt on the safety of its use. An online database search was performed for all clinical trials administering intratumoral injection of gene therapy packaged in Ad5, being conducted in the United States, and using the Common Terminology Criteria for Adverse Events (CTCAE). Studies with unclear adverse events (AE) were excluded. The primary outcome collected was grade \u22653 (AE). Analyses were performed using Fisher's exact test. Thirty-nine prospective clinical trials across a variety of cancers were identified: 14 studies of therapeutic Ad5 alone, 12 with chemotherapy, 16 with radiation, and 11 with surgery. There were 3 mortalities out of 756 patients (0.4%), which were most likely unrelated to Ad5: 1 due to hypoxic encephalopathy, 1 due to splenic vein thrombus, and 1 due to disease progression. In trials that reported total AE (grades 1\u20135), there were 284 (10.3%) grade \u22653 AE out of 2,745 total AE in 477 patients. The overall life-threatening (grade 4) AE rate was 1.4% (34\/2,425 AE in 428 patients). Overall, the most frequent grade \u22653 AE were lymphopenia (20.6% in 14 trials, 209 patients), dyspnea (8.7% in 11 trials, 208 patients), and neutropenia (8.6% in 12 trials, 174 patients). The most frequent grade 4 AE were neutropenia (4.6%), lymphopenia (3.3%), and leukopenia (3.1% in 13 trials, 192 patients). Our analyses demonstrated relative overall safety of Ad5 and warrant re-evaluation for the use of Ad5 as a delivery vector for gene therapy products.<\/jats:p>","DOI":"10.1089\/hum.2022.228","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T01:59:55Z","timestamp":1677549595000},"page":"314-324","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Review of Safety Data for Adenovirus 5 as a Delivery Vector for Intratumoral Cancer Gene Therapy"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7291-0084","authenticated-orcid":false,"given":"Yarrow","family":"Sheldon","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology, Helen F. Graham Cancer Center and Research Institute, Christiana Care, Newark, Delaware, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Chun","family":"Yoo","sequence":"additional","affiliation":[{"name":"Gene Editing Institute, Helen F. Graham Cancer Center and Research Institute, Newark, Delaware, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Kmiec","sequence":"additional","affiliation":[{"name":"Gene Editing Institute, Helen F. Graham Cancer Center and Research Institute, Newark, Delaware, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Petrelli","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Helen F. Graham Cancer Center and Research Institute, Christiana Care, Newark, Delaware, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-1551","authenticated-orcid":false,"given":"Gregory","family":"Tiesi","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Helen F. Graham Cancer Center and Research Institute, Christiana Care, Newark, Delaware, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9075-732X","authenticated-orcid":false,"given":"Shelley","family":"Warner","sequence":"additional","affiliation":[{"name":"General Surgery, Broward Health Medical Center, Fort Lauderdale, Florida, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00487-6"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700539"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2013.2527"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113354"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfw220"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9040419"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2003.08.016"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103643"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2017.04.001"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1679-3"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.07.021"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5222"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw5680"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.89"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.11.006"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22080"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083670"},{"issue":"17","key":"e_1_3_6_20_2","first-page":"4968","article-title":"Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer","volume":"62","author":"Freytag SO","year":"2002","unstructured":"Freytag SO, , Khil M, , Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res, 2002; 62(17):4968\u20134976.","journal-title":"Cancer Res"},{"issue":"21","key":"e_1_3_6_21_2","first-page":"7497","article-title":"Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer","volume":"63","author":"Freytag SO","year":"2003","unstructured":"Freytag SO, , Stricker H, , Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res, 2003; 63(21):7497\u20137506.","journal-title":"Cancer Res"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.sj.6300120"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.02.034"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302436"},{"issue":"3","key":"e_1_3_6_25_2","first-page":"798","article-title":"A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer","volume":"6","author":"Ganly I","year":"2000","unstructured":"Ganly I, , Kirn D, , Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res, 2000; 6(3):798\u2013806. Erratum in: Clin Cancer Res 2000;6(5):2120.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"e_1_3_6_26_2","first-page":"555","article-title":"A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma","volume":"9","author":"Hecht JR","year":"2003","unstructured":"Hecht JR, , Bedford R, , Abbruzzese JL, et al. A phase I\/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res, 2003; 9(2):555\u2013561.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2011.10.007"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/10430349950018229"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700568"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/78638"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy202"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1089\/10430340360535788"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02725338"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.21.13.2508"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.8219"},{"issue":"2","key":"e_1_3_6_36_2","first-page":"693","article-title":"Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies","volume":"9","author":"Makower D","year":"2003","unstructured":"Makower D, , Rozenblit A, , Kaufman H, et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res, 2003; 9(2):693\u2013702.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3301398"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0296"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.609"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.289"},{"key":"e_1_3_6_41_2","unstructured":"Nemunaitis J Linette G Ali H et al. Ad-RTS-hIL-12 + Veledimex Regulation of IL-12 Expression in Advanced Breast Cancer and Melanoma. Poster presented at American Association for Cancer Research: San Antonio TX; 2014."},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.11.001"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv196"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds523"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2001.0444"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.9.763"},{"issue":"1","key":"e_1_3_6_47_2","first-page":"93","article-title":"Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy","volume":"9","author":"Swisher SG","year":"2003","unstructured":"Swisher SG, , Roth JA, , Komaki R, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res, 2003; 9(1):93\u2013101.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01692-3"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/archoto.2009.122"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.12.016"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152506775268785"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.4174\/astr.2016.90.3.179"},{"key":"e_1_3_6_53_2","unstructured":"Mitin T. Radiation Therapy Techniques in Cancer Treatment. In: UpToDate (Loeffler JS Vora SR. ed.) Philadelphia Pennsylvania. UpToDate; 2022. Available from: https:\/\/www.uptodate.com\/contents\/radiation-therapytechniques-in-cancer-treatment [Last accessed: February 22 2022]."},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1767"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2022.228","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2022.228","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2022.228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:56:55Z","timestamp":1777449415000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2022.228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":53,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1089\/hum.2022.228"],"URL":"https:\/\/doi.org\/10.1089\/hum.2022.228","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}